



116

RECEIVED 11644

Certificate of Mailing

I hereby certify that, on the date shown below, this correspondence and its attachments are being deposited with the United States Postal Service, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, BOX: RESPONSE-NO FEE, Washington, DC 20231 in accordance with 37 C.F.R. § 1.8(a).

1 Aug 00 *Colby S. Delgado*  
Date Colby S. Delgado

NOV 03 2000

TECH CENTER 1600/2900

RECEIVED

NOV 14 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

**Applicant:**

Lars Abrahmsen, et al.

**Filed:** July 25, 1997

**Serial No.:** 08/765,695

**For:** CONJUGATE BETWEEN A MODIFIED  
SUPERANTIGEN AND A TARGET-  
SEEKING COMPOUND AND THE USE  
OF THE CONJUGATE

§  
§  
§  
§  
§  
§  
§  
§  
§  
§  
§

**Atty. Docket:** P01525US0 / 09804877

**Group Art Unit:** 1644

**Examiner:** R. Schwadron

TO XERO MAIL ROOM

AUG -9 2000

RECEIVED

9315

BOX: RESPONSE-NO FEE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**TRANSMITTAL LETTER**

Dear Sir:

Enclosed for filing in the above-identified application are the following:

- Response to Restriction Requirement; and
- Return postcard.

Please charge any fees to the deposit account of Fulbright & Jaworski L.L.P. under account number 06-2375/09804877, from which the undersigned is authorized to draw. A duplicate of this letter is enclosed for accounting purposes.


Respectfully submitted,

David L. Fox, Ph.D.  
Registration No. 40,612  
Attorney for Applicant

Date: 1 August 2000

**FULBRIGHT & JAWORSKI L.L.P.**  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
Phone: 713-651-8231  
Fax: 713-651-5246

NOV 03 2000



RECEIVED

NOV 14 2000

§ § § § § § § § § §

**§ Atty. Docket: P01525US0 / 09804877**

**§ Group Art Unit: 1644**

**§ Examiner: R. Schwadron**

RECEIVED  
AUG - 9 2000  
TC 1000 MAIL ROOM

## RESPONSE TO RESTRICTION REQUIREMENT

## AMENDMENT

Solely in view of the Restriction Requirement and election regarding same, please withdraw claims 53-57, pending allowance of generic claims.

This is in response to a Restriction Requirement dated July 3, 2000. A one month response time was set, making this paper timely by being filed on or before August 3, 2000.

In the Office Action of July 3, 2000, the Examiner noted cancellation of claims 14-35. Applicants respectfully note that these claims are presently the subject of a pending Petition under 37 C.F.R. § 1.181.

In the Office Action of July 3, 2000, the Examiner also noted generic claim 36, and called for election of a single species. Applicants elect species "A", the superantigen being staphylococcal enterotoxin A (e.g., claim 52).

RECEIVED

NOV 14 2000

Applicants note that upon examination of the generic claims, and an indication of allowable generic subject matter, all claims (all species, including claims 53-57) will be examined in this application. TECH CENTER 1600/2900

Claim 36 is generic, and hence, reads upon the elected "species A." Moreover, claims 37, 38, 44-47, and 52 read upon the elected species. Claims 53-57 are withdrawn pending allowance of generic claims.


Examination of elected claims on the merits is respectfully requested.

The Examiner is encouraged to call the undersigned attorney to discuss any matters relating to this case.

Applicants respectfully petition for any extension of time necessary to render this response timely.

Please charge any fees due or credit any overpayment to the standing account of Fulbright & Jaworski L.L.P., Deposit No. 06-2375/09804877.

Respectfully submitted,



David L. Fox, Ph.D.

Reg. No. 40,612

Attorney for Applicants

Date: 1 August 2000

**FULBRIGHT & JAWORSKI L.L.P.**  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
Telephone: 713-651-8231  
Fax: 713-651-5246